Use of vancomycin and acute kidney injury in critically ill patients with sepsis or septic shock: a retrospective observational cohort study

被引：0

作者：

Gonzalez-Delgado, D. ^{[1
]}

Vives, M. ^{[1
,2
]}

Monedero, P. ^{[1
]}

Aldaz, A. ^{[3
]}

机构：

[1] Univ Navarra, Clin Univ Navarra, Dept Anestesiol & Cuidados Intens, Pamplona, Spain

[2] Inst Invest Sanitaria Navarra, IdiSNA, Pamplona, Spain

[3] UNIV NAVARRA, Clin Univ Navarra, Dept Farm, PAMPLONA, Spain

来源：

REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION | 2025年 / 72卷 / 02期

关键词：

Acute kidney injury; Vancomycin; Sepsis; Septic shock; Nephrotoxicity; INFECTIOUS-DISEASES SOCIETY; HEALTH-SYSTEM PHARMACISTS; AMERICAN SOCIETY; NEPHROTOXICITY;

D O I：

10.1016/j.redar.2024.501657

中图分类号：

R614 [麻醉学];

学科分类号：

100217 ;

摘要：

Introduction: The independent association of vancomycin with Acute Kidney Injury (AKI) in the critically ill patient with sepsis or septic Shock is controversial. The aim of this study was to evaluate the incidence of AKI in a cohort of patients with sepsis or septic Shock with an adequate and strict monitoring of vancomycin, guided by the area under the concentration-time curve in relation to the minimum inhibitory concentration (AUC/MIC ratio). Material and methods: Retrospective cohort study on 106 patients admitted to the ICU with a diagnosis of sepsis or septic shock with vancomycin treatment, consecutively from January 2017 to December 2019. AKI was defined according to Kidney Disease Improving Global Outcomes criteria. Risk factors associated with AKI were determined by multivariable logistic regression analysis. Results: In our cohort, 28 patients out of 106 (26%) developed AKI. ICU and 30-day mortality were 18% and 22%, respectively. After multivariable logistic regression adjusted analysis, chronic liver disease was associated with AKI. Conclusion: In our retrospective cohort study on critical patients with sepsis and septic shock, treated with vancomycin adjusting the dose guided by a pharmacokinetic/pharmacodynamic monitoring to achieve the target AUC0-24/CMI ratio, the incidence of AKI was 26%. (c) 2024 The Author(s). Published by Elsevier Espana, S.L.U. on behalf of Sociedad Espanola de Anestesiolog<acute accent>& imath;a, Reanimacio<acute accent>n y Terape<acute accent>utica del Dolor. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

引用

页数：9

共 29 条

[1]

Lacave G., Caille V., Bruneel F., Palette C., Legriel S., Grimaldi D., Et al., Incidence and risk factors of acute kidney injury associated with continuous intravenous high-dose vancomycin in critically ill patients: A retrospective cohort study, Medicine (Baltimore), 96, (2017)

[2]

Bellos I., Daskalakis G., Pergialiotis V., Relationship of vancomycin trough levels with acute kidney injury risk: An exposure toxicity meta-Analysis, J Antimicrob Chemother., 75, pp. 2725-2734, (2020)

[3]

Liu J., Xie H., Ye Z., Li F., Wang L., Rates, predictors, and mortality of sepsis-associated acute kidney injury: A systematic review and meta-analysis, BMC Nephrol., 21, pp. 1-16, (2020)

[4]

Gomez H., Kellum J.A., Sepsis-induced acute kidney injury, Curr Opin Crit Care., 22, pp. 546-553, (2016)

[5]

Mitevska E., Wong B., Surewaard B.G.J., Jenne C.N., The prevalence, risk, and management of methicillin-resistant Staphylococcus aureus infection in diverse populations across Canada: A systematic review, Pathogens., 10, 4, (2021)

[6]

Rybak M.J., Le J., Lodise T.P., Levine D.P., Bradley J.S., Liu C., Et al., Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists, Am J Heal Pharm., 77, pp. 835-863, (2020)

[7]

Bakke V., Sporsem H., von der Lippe E., Nordoy I., Lao Y., Nyrerod H.C., Et al., Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study, Acta Anaesthesiol Scand., 61, pp. 627-635, (2017)

[8]

Zhang Y., Wang T., Zhang D., You H., Dong Y., Liu Y., Et al., Therapeutic drug monitoring coupled with bayesian forecasting could prevent vancomycin-associated nephrotoxicity in renal insufficiency patients: A prospective study and pharmacoeconomic analysis, Ther Drug Monit., 42, pp. 600-609, (2020)

[9]

Tsutsuura M., Moriyama H., Kojima N., Mizukami Y., Tashiro S., Osa S., Et al., The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing, BMC Infectious Diseases, 21, (2021)

[10]

Aljefri D.M., Avedissian S.N., Rhodes N.J., Postelnick M.J., Nguyen K., Scheetz M.H., Vancomycin area under the curve and acute kidney injury: a meta-analysis, Clin Infect Dis., 69, pp. 1881-1887, (2019)

← 1 2 3 →